Swedish’s Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment launches new clinical trial to treat brain cancer with the Nativis Voyager Radio Frequency Energy (RFE) Medical Device
The Swedish Neuroscience Institute’s Ben & Catherine Ivy Center for Advanced Brain Tumor Treatment today announced a new clinical trial for treating brain cancer. The trial (ID no. NCT02296580 – “A Feasibility Study of the Nativis Voyager System in Patients with Recurrent Glioblastoma Multiforme”), sponsored by Nativis, Inc. in Seattle – will investigate the safety and efficacy of the Nativis Voyager RFE medical device in humans. The device has shown promise in preclinical studies.
Swedish and Oregon Health & Science University celebrate historic milestone in honor of National Donate Life Month
SEATTLE, April 27, 2015 – Organ donor networks are turning to local communities to save lives through multiple organ exchanges. Swedish and Oregon Health & Science University (OHSU) today announced the Pacific Northwest Regional Kidney Paired Exchange Program’s first three-way kidney transplant, which saved the lives of three patients. Six surgical procedures, four at Swedish and two at OHSU, involving more than 30 medical professionals were performed in a single day.
The paired exchange is the result of a regional partnership between Swedish, Virginia Mason, Sacred Heart Medical Center in Spokane and Oregon Health & Science University. The organizations are participating in a clinical trial, sponsored by BiologicTx, to examine how regional paired exchange may improve kidney transplant rates for patients in the Northwest.
SEATTLE, April 24, 2015 — Swedish Ballard will open a new Level II Nursery on Monday, April 27. The Level II Nursery allows for premature babies— born as early as 34 weeks gestational age — to receive specialized, around-the-clock care from a trained team of experts.
First hospital in Washington state to earn this honor
We are excited to announce that Swedish Ballard has received the Pathway to Excellence® designation from the American Nurses Credentialing Center (ANCC), making it the first hospital in Washington state to earn this honor.
The Pathway to Excellence® program recognizes health care and long-term care organizations for positive practice environments where nurses excel. To qualify, organizations must meet 12 Pathway Practice Standards essential to an ideal nursing practice environment.
The adoption of Syapse Precision Medicine Platform will help deliver large-scale genomic and clinical data to enhance patient care
SEATTLE, April 23, 2015 – The Swedish Cancer Institute (SCI), one of the Northwest’s leading cancer treatment centers, announced today the adoption of Syapse Precision Medicine Platform to enhance its Personalized Medicine Program. The innovative software platform will enable clinicians to better integrate genomic information into patient care and move critical cancer research forward.
The Personalized Medicine Program, launched in April 2014, combines advanced treatments based on the “molecular fingerprint” of a tumor with individualized emotional and physical supportive care. SCI’s gene alteration panel, developed in partnership with CellNetix Pathology & Laboratories, is based on a focused set of gene alterations that are most relevant to cancer treatments. By combining gene alteration data with the clinical decision support of the Syapse platform, patients may receive tailored therapies or targeted clinical trials specific to their molecular fingerprint instead of treatments based solely on the origin of their cancer.
More information about the Swedish newsroom
Explore the rest of the Swedish blog
Swedish has a social media policy
See who is blogging at Swedish
Check out more from Swedish:
See who else is blogging at Swedish